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To the Editor: 
  
Persistent hepatitis E virus (HEV) infection is recognised in immunocompromised 
patients, particularly solid organ transplant (SOT) recipients [1]. The majority of 
cases are caused by genotype 3 (G3) HEV [1]. Ribavirin monotherapy is considered 
first-line when the reduction of immunosuppression is contraindicated or 
unsuccessful [2]. Treatment failure and relapse is recognised with limited alternative 
treatment options [3]. Current guidelines suggest re-treatment with a prolonged 
course of ribavirin or, in cases of intolerance or non-response, PEG-Interferon (if not 
contraindicated) [2, 4]. Sofosbuvir has been shown to inhibit G3 HEV in vitro, but to 
date no clinical cases treated with Sofosbuvir have led to HEV clearance [3]. Newer 
therapies are being investigated, but none have reached clinical use. We describe a 
case of persistent HEV infection demonstrating clinical phenotypic resistance to 
conventional treatments and the outcome of convalescent plasma (CP) therapy. 
The patient was a 78 year-old male with persistent HEV infection on a background of 
underlying gastric marginal lymphoma on mucosa associated lymphoid tissue with 
omental involvement. He had been treated with chemotherapy, including RCVP 
[rituximab, cyclophosphamide, vincristine, prednisolone], R-CHOP [rituximab, 
cyclophosphamide, hydroxydaunomycin, vincristine, prednisolone] and radiotherapy 
five years previously and cured. As a result of this treatment he had chronic 
autoimmune neutropenia, which was supported with granulocyte colony stimulation 
factor. He was diagnosed with HEV viraemia (HEV G3c, 5.6x106 IU/ml, anti-HEV IgG 
25.6 WHO units/ml) in March 2016, although he was first noted to have raised liver 
enzymes in November 2015.  He was treated in early 2016 with a 12-week course of 
ribavirin (400mg twice daily; eGFR 82 ml/min/1.73m2; body weight 62kg). HEV RNA 
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was not detected in blood at weeks eight and twelve of treatment, or in stool at the 
end of treatment. He relapsed six weeks after completing treatment. He received a 
second course of ribavirin 400mg twice daily for six months, but HEV RNA levels 
remained high (6.0 x 105 IU/ml) so ribavirin was discontinued as he was experiencing 
side effects. On cessation of ribavirin he had a significant rise in liver enzyme levels. 
He was next treated with PEG-Interferon and ribavirin (PEGASYS 180mcg weekly 
and ribavirin 400mg twice daily) for nine months but with no significant fall in HEV 
RNA. Illumina whole genome sequencing (HEV target-enrichment protocol, 
supplementary methods [5, 6]) revealed the development of multiple mutations 
(K1383N, D1384G, and G1634R) in the RNA-dependent RNA-polymerase region 
previously described in patients failing ribavirin therapy [3]. A further previously 
undescribed mutation, V1305I, was also detected during the third treatment course. 
Treatment and results are summarised in Figure 1. 
In the absence of any other available treatment we attempted treatment with CP, 
whilst the patient continued therapy with PEG-interferon and ribavirin. 
Four potential plasma donors were identified from blood donors who had had a 
recent primary HEV infection (<100 days) with development of high levels of 
detectable anti-HEV IgG (S/CO >15.0) and who had at least one HEV RNA negative 
plasma sample to demonstrate viral clearance. Archived samples were quantified for 
anti-HEV IgG by WHO units/ml and tested for the ability to neutralise HEV antigen 
(HEV-Ag) (Supplementary figure 1). Anti-HEV IgG and HEV-Ag were detected using 
commercial assays (Fortress Diagnostics, Antrim, Northern Ireland, UK); HEV-Ag 
neutralisation was determined by a recently described method [7]. HEV RNA was 
detected using an internally-controlled and validated quantitative HEV PCR (limit of 
detection 22 IU/ml) [8]. Two donors were selected (donor C and D) whose plasma 
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had greater than 10 WHO units/ml of anti-HEV IgG and highest HEV-Ag neutralising 
activity when tested at equivalent levels of anti-HEV IgG (between 2 and 5 WHO 
units/ml). Donor D had previously been infected with a G3c virus, but technical 
limitations prevented sequencing of the virus previously infecting donor C. 
Established apheresis protocols were followed [9]; a convalescent HEV plasma team 
arranged plasma collections from the two selected donors. Plasma was collected 
from donor C over 9 weeks (3x280ml; 16-25 weeks from initial viraemic sample) and 
from donor D over 4 weeks (5x280ml; 31-35 weeks from initial viraemic sample). The 
donations were tested for blood borne viruses in line with national donor guidelines 
[10]. The treatment was approved by the Newcastle-upon-Tyne Hospitals NHS 
Foundation Trust Clinical Governance Team and the Trust Medical Director. The 
patient provided written informed consent to the procedure and subsequent 
publication. The patient was admitted to the Liver unit, Freeman Hospital, Newcastle 
for observation and was given three transfusions of 560ml CP 12 hours apart.  Blood 
samples were taken according to the protocol (supplementary table 1). At baseline 
his total white cell count was 7.13x109/l, (neutrophils 4.68x109/l; lymphocytes 
1.1x109/l) and total serum IgG was 7.6 g/l, IgA 1.09 g/l and IgM 10.31g/l with an IgM 
paraprotein. 
The patient reported no adverse effects during or after infusions. All observations 
(temperature, pulse rate, blood pressure, respiratory rate, oxygen saturations and 
level of consciousness) were normal during infusion and 2 hours post infusion. Blood 
tests showed no change in liver enzymes, blood counts or renal function during or 
after the infusion. Levels of plasma HEV RNA in the patient did not vary significantly 
after infusion or in the 21-day follow-up period (Figure 2).  Levels of detectable HEV-
Ag showed a consistent pattern of falling at the 1-hour post-infusion timepoint, but 
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this was not sustained at 3-hours post-infusion. Nevertheless each baseline pre-
infusion sample contained less detectable HEV-Ag than the previous baseline 
sample (Figure 2a). HEV-Ag levels returned to baseline in the days following 
completion of infusions. Of particular note, the levels of detectable anti-HEV IgG 
showed a similar pattern to HEV-Ag levels, with a fall of 5.41, 6.09 and 3.00 WHO 
units/ml compared with the pre-infusion sample for infusions 1, 2 and 3 respectively 
(Figure 2b). 
The rationale for CP as a therapeutic option was to provide higher levels of 
neutralising antibodies against HEV. Patients with persistent HEV infection appear to 
have a lower proportion of anti-HEV IgG capable of neutralising HEV-Ag than those 
in convalescence from acute HEV infection [11]. Furthermore, studies have 
demonstrated a protective effect of CP in cynomolgus monkeys after an HEV 
challenge and a possible protective effect of replacement immunoglobulin against 
persistent HEV infection amongst antibody-deficient patients [11].  In our case, 
treatment with HEV CP therapy was not effective in leading to a sustained reduction 
in HEV load. Understanding the reason for therapeutic failure is crucial to guide 
future research. CP has demonstrated mixed results for treating viral infections, with 
successful outcomes in the treatment of severe acute respiratory syndrome 
coronavirus and influenza A virus, but inconclusive results for Ebola virus disease 
[13, 14]. Since HEV has no latent stage nor does it integrate into host DNA there is 
biological plausibility that CP could be effective in treating HEV infection. However, 
to our knowledge CP therapy has not been used in an attempt to clear persistent 
HEV infection.  
The mode of action of CP therapy is not well understood, but it is expected that 
neutralisation plays a significant role. HEV virions in plasma appear to circulate as 
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quasi-enveloped particles which may protect them from neutralising antibodies and 
thus explain the failure of CP [15]. However, passively transferred antibodies are 
effective in preventing liver disease after Hepatitis A virus (HAV) infection which has 
similar quasi-enveloped virions [16]. Access to important neutralisation epitopes may 
still be possible in endosomes after removal of the membrane, which is postulated 
for HAV [17].  
It is anticipated that higher titres of neutralising antibody will have greater therapeutic 
effect [18]. Therefore we identified potential high-titre apheresis donors amongst 
blood donors in convalescence from HEV infection by comparison of anti-HEV IgG 
titre and HEV-Ag neutralising capability. Despite this, our patient’s samples post 
infusion consistently had lower detectable anti-HEV IgG of between 3 and 6 WHO 
units/ml. This is intriguing and remains difficult to explain and we believe is not 
adequately explained purely by haemodilution from plasma volume, since pre-
infusion levels of anti-HEV IgG in the plasma of our patient (25.6 WHO units/ml) 
were similar to or lower than the levels of detectable anti-HEV in donors C (21.6-22.7 
WHO units/ml) or D (44.8-52.9 WHO units/ml). Nevertheless, there may simply have 
been insufficient antibodies in the plasma donations for therapeutic effect, especially 
given the fact that our patient was already seropositive with detectable anti-HEV IgG.  
Crucially we did not observe a significant fluctuation in the HEV RNA following any of 
the plasma infusions. However, we did observe a fall in HEV-Ag levels following 
each of the three infusions. Recent studies have identified three forms of this ORF2 
antigen [19]. It would be informative to understand whether all three forms of HEV-
Ag fell post-infusion in our patient or whether the secreted form preferentially fell. We 
anticipate the fall in HEV-Ag levels we observed is due to binding and neutralisation 
of the secreted form of ORF2, since we would have expected the viral load to fall if 
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virion-associated HEV-Ag had been bound and cleared from the circulation [20]. 
Since the importance of host immunosuppression to the success of CP therapy is 
unknown we cannot be sure how important a functioning immune system is for 
treatment efficacy. Our patient had been heavily immunosuppressed previously and 
suffered with chronic neutropenia. Immune dysfunction may hinder the efficacy of CP 
therapy. The relative importance of B- and T-cell responses in clearing HEV infection 
is not understood, however T-cell responses are known to be important. HEV-
specific T-cell responses detected in exposed healthy controls are absent in SOT 
recipients with persistent HEV infection and reducing immunosuppression targeting 
T-cells (e.g. tacrolimus) can lead to HEV clearance [21].  
We have described an unsuccessful treatment attempt of CP therapy in a case of 
treatment-refractory persistent HEV infection. New treatment approaches are 
required for those patients who fail conventional therapy. 
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Legend Figure 1. Clinical course of patient prior to convalescent plasma therapy. Clinical course of patient prior to CP 
therapy where (A) depicts viral load, liver enzyme values, antiviral treatment and in boxes the detection of mutations in our patient 
which have been reported in previous cases of treatment failure and (B) shows the relative proportion of amino acids detected at 
loci where mutations apparently became fixed in our patient (V1305I, K1383N, D1384G, G1634R) and previously described 
mutations (V1479I). The V1305I has not been previously reported in association with treatment failure, however was only detected 
at the final timepoint sampled during the third ribavirin course with PEG-Interferon. The open circles represent samples submitted 
for Illumina whole genome sequencing. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CP, 
convalescent plasma; IU, international units; PEG-IFN, pegylated interferon; RBV, ribavirin; ULN, upper limit of normal; VL, viral 
load. 
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Legend Figure 2. HEV markers throughout convalescent plasma therapy. 
Response of HEV-Ag levels (A) and anti-HEV IgG levels (B) taken from patient in 
receipt of CP therapy. The patient was given three infusions of CP (~560ml) 12 
hours apart. Samples were diluted 1 log and 2 log in normal human plasma prior to 
testing for anti-HEV IgG and HEV-Ag respectively. Abbreviations: CP, convalescent 
plasma; d, days; ELISA, enzyme-linked immunosorbent assay; hr, hours; IU, 
international units; S/CO, sample over cut-off of optical density values. 
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